CYB704

ocrelizumab biosimilar · Sandoz

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CYB704, covering 2026-03-05 to 2026-03-05. Get the full timeline:

Most recent: Clinical Trial Update: Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis [Phase 3]

See pricing